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ABSTRACT 
 
          Metastatic prostate cancer (PC) is lethal and lacks effective strategies for prevention or treatment, 
requiring novel therapeutic approaches. Interleukin-6 (IL-6) is a cytokine which has been linked with PC 
pathogenesis by multiple studies. However, the direct functional role(s) of IL-6 in PC growth and 
progression have been unclear. In the present study, we show that IL-6 is produced in distant metastases 
of clinical PCs. IL-6 activated signaling pathways in PC cells induced a robust 7-fold increase in 
metastases formation in nude mice. We further show that IL-6 promoted migratory PC cell phenotype, 
including increased PC cell migration, microtubule re-organization and heterotypic adhesion of PC cells 
to endothelial cells. IL-6-driven metastasis was predominantly mediated by Stat3 and to lesser extent by 
ERK1/2. Most importantly, pharmacological inhibition of Jak1/2 by AZD1480 suppressed IL-6-induced 
signaling, migratory PC cell phenotypes and metastatic dissemination of PC in vivo in nude mice. In 
conclusion, we demonstrate that the cytokine IL-6 directly promotes PC metastasis in vitro and in vivo 
via Jak-Stat3 signaling pathway, and that IL-6-driven metastasis can be effectively suppressed by 
pharmacological targeting of Jak1/2 using Jak1/2 inhibitor AZD1480. Our results therefore provide a 
strong rationale for further development of Jak1/2 inhibitors as therapy for metastatic PC. 
 
 
 
 4 
INTRODUCTION 
 
          Development of metastatic disease is one of the key challenges in clinical management of prostate 
cancer (PC) (1). While localized PC can be effectively managed by surgery and radiation, the single 
greatest cause of PC morbidity and mortality is due to formation of distant metastases (2-6). 
Identification of the molecular changes leading to metastatic dissemination of PC is critical for 
development of therapeutic interventions to prevent PC progression to the lethal metastatic form of the 
disease. 
          Interleukin-6 (IL-6) is a multifunctional cytokine implicated in PC pathogenesis (7).  IL-6 and IL-
6 receptors are expressed in PC, with elevated expression in high Gleason score PCs (8, 9). 
Concomitantly, IL-6 has been found to be elevated in the sera of patients with castrate-resistant prostate 
cancer (CRPC), and IL-6 serum levels correlate with markers of PC progression (10-16). Furthermore, 
IL-6 is expressed at high levels in the androgen-independent PC cell lines PC3 and DU145 (15), while 
the androgen-dependent PC cell line LNCaP expresses lower IL-6 levels (17). IL-6 binds to the IL-6 
receptor, a complex which is composed of two subunits: IL-6-R alpha (IL-6–specific) and gp130 (shared 
by IL-6 and related cytokines) (5, 18, 19).  IL-6 first binds to the IL-6R alpha subunit (20), which then 
leads to recruitment of the signal-transducing gp130 subunit. Association of gp130 with IL-6 and IL-6R 
alpha leads to formation of the high-affinity IL-6 receptor complex and homodimerization of two gp130 
subunits, resulting in activation of downstream Jak1/2-Stat3, ERK1/2-MAPK and/or PI3K-Akt signaling 
in PC cells (5, 19, 21-24). In androgen receptor (AR)-positive PC cell lines, it has been suggested that 
some of the biological effects of IL-6 are mediated via IL-6 induction of AR signaling (25-27). 
          The existing literature on IL-6 regulation of PC cell growth and viability have been controversial, 
including reports documenting both growth-stimulatory and inhibitory effects (28-34). Our previous 
work demonstrated that Stat3 activation predominantly affects PC progression by inducing metastatic 
behavior of PC cells in vitro and massive metastasis formation in vivo, rather than promoting PC cell 
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growth (35, 36). Given that Stat3 is one of the key IL-6-activated signaling molecules in PC, we 
hypothesized that IL-6 promotes metastatic progression of PC.  
          Here, we show that the IL-6 protein is expressed in the majority of distant metastases of clinical 
PCs. IL-6 induced a robust increase in PC metastasis formation in nude mice in an experimental 
metastasis assay, which was accompanied by IL-6-driven PC cell migration and heterotypic adhesion in 
vitro. We further demonstrate that IL-6 stimulation leads to activation of Jak1/2 and predominantly Stat3 
signaling pathway in AR-negative and AR-positive PC cells. Most important from a therapeutic 
perspective, pharmacological targeting of Jak1/2 by a potent adenosine triphosphate (ATP)-competitive 
small-molecule inhibitor of Jak1/2 kinase, AZD1480 (37) prevented IL-6-driven development of a 
migratory PC cell phenotype in vitro and suppressed IL-6-driven metastatic dissemination of PC in nude 
mice. In summary, Jak1/2 may represent a therapeutic target proteins for PC, and prevention of 
metastatic progression of primary PC in patients could potentially be achieved by small-molecule Jak1/2 
inhibitors currently in clinical development (38, 39).  
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MATERIALS AND METHODS 
 
          Clinical samples of distant metastases of PCs. Archival and de-identified, formalin-fixed, 
paraffin-embedded specimens of distant metastases of clinical PCs (n=87) (regional lymph nodes, n=36; 
bone, n=3; other organs, n=48) (Table 1) were obtained from University of Turku in Finland. The 
immunohistochemical analysis of the de-identified archival tissues was granted an exemption from full 
IRB review by Thomas Jefferson University.  
                    Cell culture and reagents. Human prostate cancer cell lines CWR22Rv1, DU145 and 
LNCaP  (ATCC, Manassas, VA) were cultured
 
in RPMI 1640 (Mediatech, Herndon, VA, #15-041-CV) 
containing 10% fetal
 
bovine serum (FBS; Quality Biological, Gaithersburg, MD, #100106) and 
penicillin/streptomycin (Mediatech, Inc., 50 IU/ml and 50 µg/ml, respectively, #30-002-CL). LNCaP 
cells were cultured in the presence of 0.5 nM dihydrotestosterone (DHT; Sigma, St. Louis, MO, #512-
18-6). CWR22Rv1 cells were obtained in 2005 from Dr. Thomas Pretlow (Casewestern Reserve Univ.) 
and LNCaP and DU145 cells in 2009 from ATCC. AZD1480 (37) was provided by AstraZeneca. IL-6 
producing lentivirus (LV-II-human-IL-6 virus (3.8 x 10
8
 IU/ml) was purchased from Capital 
Biosciences (Rockville, MD) and recombinant IL-6 was purchased from ProSpec Protein Specialists 
(Brunswick, NJ, #CYT-213). 
          Immunostaining of paraffin-embedded tissue sections. Immunohistochemistry of distant PC 
metastases was performed as described previously (35, 36, 40-42). The primary antibody IL-6 mAb 
(Santa Cruz Biotechnology; sc-130326) was used at a concentration of 5µg/ml.  
           Enzyme-linked immunosorbent assay (ELISA). DU145 were mock-infected or infected with 
lentivirus expressing the IL-6 gene (MOI=5), followed by collection of cell culture media at 4, 10 and 
20 days and analysis for IL-6 protein levels by enzyme-linked immunosorbent assay (ELISA) according 
to the manufacturer’s instructions (R&D Systems, Minneapolis, MN, USA, #Q6000B). 
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          Homotypic cell adhesion assay. DU145 and CWR22Rv1 cells were seeded on Matrigel (BD 
Biosciences, #354234), serum-starved for 18 h and treated with recombinant IL-6 (5 nM) for 24, 48, 72 
or 96 h.      
          Heterotypic cell adhesion assay. DU145 cells, cultured in the presence of 1% charcoal-stripped 
fetal bovine serum (CS-FBS), were infected with IL-6 and Stat3-shRNA and/or ERK1/2-shRNA 
lentiviruses at (MOI=5) and/or treated with recombinant IL-6 (5 nM) with or without AZD1480 (800 
nM). DU145 and CWR22Rv1 cell adhesion to the endothelial cells was determined as described 
previously (43) and in the Suppl. Methods. 
          Immunofluorescence cytochemistry of tubulin.  DU145 cells grown on cover glasses were 
serum-starved for 18 h, treated with recombinant IL-6 (5 nM) and fixed 48 h after IL-6 treatment with 
4% paraformaldehyde. Tubulin immunocytochemistry was performed as described previously and in the 
Suppl. Methods.  
          Boyden chamber migration assay. DU145 and CWR22Rv1 cells were cultured in 1% CS-FBS, 
phenol-red free RPMI medium in the presence or absence of IL-6 (5 nM) for 72 h. In the indicated 
treatment groups, the cells had been infected with lentiviruses expressing control-shRNA, Stat3-shRNA 
and/or ERK1/2-shRNA 24 h prior to the start of the IL-6 treatment. Also, in the indicated treatment 
groups, AZD1480 (800 nM) had been added to the culture medium 1 h prior to the start of the IL-6 
treatment.  The cells were counted and suspended to the upper chambers (2.5 x 10
4
 cells/chamber) of the 
motility chamber system (8.0 µm pore size; BD BioSciences, #353097) using FBS (10%) as the 
chemoattractant, as described previously (35, 43). After 16 h, the cells that had traversed the membrane 
pores were fixed, stained and counted. Each experiment was repeated four times. 
          Protein solubilization, immunoprecipitation and immunoblotting. CWR22Rv1, DU145 and 
LNCaP cells were solubilized and immunoprecipitations and immunoblottings were performed as 
described previously (35, 36, 43-46). Antibodies used for immunoprecipitation and immunoblotting are 
 8 
described in Suppl. Methods.  
            Cell viability assay. DU145 cells were
 
treated with AZD1480 or DMSO (as vehicle control) or 
infected with IL-6 expressing lentivirus (MOI=5) for 72 h. Cell viability was analyzed by the CellTiter 
96
®
 AQueous Assay kit (Promega, #G3580) according to the manufacturer's
 
protocol.                      
          Tail-vein injections of human prostate cancer cells. Male athymic nude mice (for DU145 cells) 
were purchased from Taconic (Germantown, NY) and SCID mice (for CWR22Rv1 cells) were 
purchased from the Jackson Laboratory (Bar Harbor, ME), and cared for according to institutional 
guidelines. DU145 and CWR22Rv1 cells were infected with IL-6 lentivirus (MOI=5) alone or in 
combination with Stat3-shRNA lentivirus (MOI=5) and/or ERK1/2-shRNA (MOI=5) lentivirus. After 
24 h, 1 x 10
6
 cells were suspended in 0.2 ml of PBS and injected into the lateral tail veins of nude mice 
using a 27-gauge needle, as described previously (35, 36, 43). In some of the experiments, the  mice 
were treated daily by oral gavage of AZD1480 at 50 mg/kg body weight or vehicle (0.5% HPMC/0.1% 
Tween-80) starting on day 3 until the mice were sacrificed (8 weeks after cell inoculation). The lungs 
were perfused with 1.5 ml of 15% India Ink dye in 3.7% formalin, removed and bleached in Fekete’s 
solution (70% ethanol, 3.7% formaldehyde, 0.75M glacial acetic acid). The livers were fixed in 10% 
formalin. Lung surfaces were photographed and number of surface lung metastases was scored. 
          Statistics. Statistical analyses are provided in Suppl. Methods. 
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RESULTS 
 
          IL-6 is expressed in the majority of distant metastases of clinical PCs. To test the hypothesis 
that IL-6 promotes metastatic behavior of human PC cells, we first determined the frequency of IL-6 
expression in clinical PC metastases (n=87) using immunohistochemical detection of IL-6 in paraffin-
embedded tissue sections. Representative prostate cancer metastases positive or negative for IL-6 are 
presented in Figure 1A. A positive immunoreaction for IL-6 was detected in 78% (68/87) of epithelial 
cells in PC metastases (Table 1). In PC metastases to regional lymph nodes, an intense immunoreaction 
for PC was detected in 89% (32/36) of the specimens, while IL-6 was expressed in 2 out of 3 bone 
metastases. Additionally, IL-6 was expressed in 71% (34/48) of PC metastases to distant organs other 
than bone. In summary, our results indicate that the majority of PC metastases robustly express IL-6 
protein.  
          IL-6 induces experimental metastases formation in nude mice. To determine if IL-6 affects 
metastatic dissemination of human PC cells in vivo, we performed in vivo experimental metastases 
assays in nude mice. We generated lentivirus expressing the IL-6 gene, and evaluated the efficacy of this 
lentiviral construct in producing IL-6 in PC cells by enzyme-linked immunosorbent assay. Lentiviral 
expression of the IL-6 gene in DU145 cells resulted in a 3-fold increase in IL-6 production into the 
culture medium (2.2 ng/ml; 0.11 nM)  at 20 days compared to mock-infected cells (0.7 ng/ml; 0.04 nM) 
(Fig. 1B).  Next, we infected DU145 cells with the IL-6 lentivirus and 24 h after the lentiviral gene 
delivery (MOI=5), DU145 cells were inoculated in athymic nude mice through tail vein injection (1 x 
10
6
 cells per mouse). After 8 weeks, the lungs were harvested, stained with India Ink, bleached with 
Fekete’s solution and scored for surface lung metastases. As demonstrated in Figure 1C, the number of 
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metastases in mice injected with DU145 cells infected with IL-6 lentivirus was robustly increased when 
compared to control mice. Quantitatively, injection of DU145 cells infected with IL-6 lentivirus resulted 
in an average of 212 (S.E.M. = 102) metastases per lung, as compared with 3 metastases per lung using 
mock-infected DU145 cells (S.E.M. = 2.0). As depicted visually in Figure 1C (lower panel), IL-6 
robustly promoted development of metastases in the lungs of nude mice (p=0.0053), evidenced by the 
density and large number of white metastatic nodules present throughout the lungs. To verify the 
concept that IL-6 promotes PC metastases formation in vivo, a second cell line CWR22Rv1, which is 
AR-positive, was infected with lentivirus expressing the IL-6 gene (MOI=5) and inoculated in mice 
through tail vein injections (1 x 10
6
 cells per mouse). IL-6 increased liver metastases formation of 
CWR22Rv1 cells significantly (Suppl. Fig. 1A) as evidenced by increased liver weight (p=0.0079) 
(Suppl. Fig. 1B) and decreased overall survival (Suppl. Fig. 1C). Collectively, these data are the first 
demonstration that IL-6 increases the intrinsic ability of PC cells to metastasize in vivo.  
          IL-6 promotes PC cell migration, decreases homotypic adhesion of PC cells and increases 
heterotypic adhesion of PC cells to endothelial cells. Given that IL-6 was capable of inducing 
extensive metastases formation in vivo, we next investigated if IL-6 is involved in the regulation of 
metastatic behavior of prostate cancer cells in vitro. Development of metastases in the lungs and the 
livers of  mice following tail-vein injection of PC cells requires a cascade of well-characterized 
biological events, including decreased homotypic adhesion, increased heterotypic adhesion, 
extravasation, increased migration, increased invasion of cells into the extracellular matrix and increased 
cell viability during migration (47). In Boyden chamber assays, migration of DU145 and CWR22Rv1 
cells was increased by 46% (p=0.045) and 200% (p<0.0001), respectively, by IL-6 (5 nM) after 16 h 
incubation using 10% FBS as the chemoattractant (Fig. 2A and Suppl. Fig. 2A). Furthermore, IL-6 
induced morphological changes characteristic of motile cells (Fig. 2B). Specifically, microtubules are 
known to be important for intrinsic cell polarization and directional cell migration, and can be linked to 
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actin polymers directly or indirectly through intermediate proteins or signaling molecules (48-50). 
DU145 cells were stained for the presence of α-tubulin using FITC-conjugated secondary antibodies 
(Fig. 2B). IL-6 (5 nM) induced outward polarization of microtubules from the centrosomes, forming a 
dense meshwork facing the plasma membrane. In contrast, the microtubule network in control DU145 
cells remained disrupted, which is characteristic of non-migratory cells (Fig. 2B).  
          To investigate if IL-6 disrupts homotypic adhesion of PC cells, we examined the effects of IL-6 
on DU145 and CWR22Rv1 cells cultured on Matrigel, a collagen-rich extracellular matrix that provides 
a more physiological growth environment than plastic. DU145 cells (Fig. 2C) and CWR22Rv1 cells 
(Suppl. Fig. 2B) were treated with recombinant IL-6 (5 nM) and cultured on Matrigel for 4 days. In the 
control group, DU145 cells grew as adherent sheets of cells attached to Matrigel. In contrast, cells 
treated with IL-6 (5 nM) were partly dispersed as single cells or small, scattered cell clusters (Fig. 2C 
and Suppl. Fig. 2B). These data provided evidence that IL-6 disrupts homotypic adhesion of DU145 and 
CWR22Rv1 cells, reducing epithelial cell-to-cell contact and suggesting increased migratory and 
invasive potential. 
Finally, the initial arrest and attachment of cancer cells to vascular endothelium precedes 
extravasation from the bloodstream, and is a crucial step in the metastatic cascade. To determine if IL-6 
promotes adhesion of PC cells to vascular endothelial cells, IL-6 was expressed in DU145 and 
CWR22Rv1 cells using IL-6 lentivirus for 72 h and tested for adhesion to two types of human 
endothelial cells: human umbilical vein endothelial cells (HUVEC) and human bone marrow endothelial 
cells (HBMEC). Notably, IL-6 increased binding of DU145 cells to HUVEC cells by 67% (p=0.0022) 
and to HBMEC cells by 125% (p=0.0079) (Fig. 2D). In addition, IL-6 increased binding of CWR22Ev1 
cells to HBMEC cells by 51% (p<0.001) (Suppl. Fig. 2C). Collectively, the results presented here 
indicate that IL-6 induces a migratory phenotype in PC cells and increases heterotypic adhesion of PC 
cells to endothelial cells.     
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          Stat3 is the key mediator of IL-6-driven development of a migratory PC cell phenotype in 
vitro. To identify signaling pathways that mediate the biological effects of IL-6 in DU145 cells, cells 
were starved overnight, stimulated with IL-6 (5 nM) for 30 min and immunoblotted for active 
phosphorylated forms of Stat3, ERK1/2 and Stat5a/b. As shown in Fig. 3A (i and ii), both Stat3 and 
ERK1/2, but not AKT or Stat5a/b, were activated by IL-6 stimulation in the absence of serum in the 
culture medium in DU145 cells. Moreover, IL-6 activated Jak2 in CWR22Rv1, DU145 and LNCaP cells 
and Jak1 in DU145 cells, while Jak1 was not expressed in LNCap and CWR22Rv1 cells  (Fig. 3A (iii)). 
In CWR22Rv1 cells, IL-6 activated only Stat3 but not ERK1/2 or Akt (Suppl. Figs. 3A and 3B). Next, 
we generated lentiviruses expressing shRNAs targeting Stat3, ERK1 and ERK2, and verified protein 
knockdown efficiency in DU145 cells by Western blotting (Fig. 3B). To evaluate the contributions of 
Stat3 and ERK1/2 signaling to IL-6-induced PC cell migration, DU145 cells were infected with 
lentiviruses expressing Stat3 shRNA and/or ERK1/2 shRNA and treated with IL-6 (5 nM) for 72 h, after 
which the cells were tested for migratory potential in Boyden chamber assays for 16 h. IL-6 significantly 
increased migration of DU145 cells (p=0.0017) (Fig. 3C). Genetic knockdown of Stat3 (p=0.029) as 
well as ERK1/2 (p=0.057) inhibited IL-6-induced migration of DU145 cells cultured in the presence of 
FBS (Fig. 3C). 
To evaluate if Stat3 and ERK1/2 pathways mediate IL-6-induced heterotypic adhesion of PC 
cells to endothelial cells, DU145 cells were infected with lentiviruses expressing IL-6, Stat3 shRNA 
and/or ERK1/2 shRNA for 72 h and tested for adhesion to HBMEC cells. IL-6 significantly increased 
binding of DU145 cells to HBMEC cells (p=0.0001). Genetic knockdown of either Stat3 (p=0.0006) or 
ERK1/2 (p=0.0006) reduced IL-6-induced PC cell adhesion to HBMEC endothelial cells (Fig. 3D). In 
conclusion, the data presented here demonstrate that Stat3 signaling pathway predominantly mediates 
IL-6-induced PC cell migration and heterotypic adhesion in DU145 and CWR22Rv1 cells, while 
ERK1/2 may also contribute to mediation of IL-6 effects in DU145 cells to a lesser extent.   
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          Pharmacological targeting of Jak2 by AZD1480 suppresses IL-6-induced Stat3 and ERK1/2 
signaling and development of a migratory PC cell phenotype. Since Jak1 and Jak2 are the key 
tyrosine kinases activated by IL-6 in PC cells, we wanted to determine if the small-molecule Jak1/2-
inhibitor AZD1480 (37) is capable of suppressing IL-6-induced metastatic behavior of human PC cells 
in vitro. We first tested the efficacy of AZD1480 in blocking IL-6-activated cell signaling in PC cells. 
AZD1480 inhibited IL-6-induced phosphorylation of Stat3 by approximately 50% (IC50) at a 
concentration of 9.4 nM in DU145 cells, while the IC50s for IL-6-induced ERK1 and ERK2 
phosphorylation were 26 and 21 nM, respectively (Fig. 4A). Next, we evaluated if AZD1480 suppresses 
IL-6-driven migration of DU145 cells (Fig. 4B). DU145 cells were treated with or without recombinant 
IL-6 (5 nM) for 72 h in the presence or absence of AZD1480 (800 nM), after which equal numbers of 
cells per group were assayed for migratory ability in Boyden chambers for 16 h. IL-6 increased 
migration of DU145 cells by 48% (p=0.057), which was potently suppressed by AZD1480 (p=0.029) 
(Fig. 4B). Western blotting of cell lysates from parallel wells indicated that AZD1480 primarily 
inhibited Stat3 and ERK1 phosphorylation, with less inhibition of ERK2 phosphorylation, during long-
term IL-6 treatment of DU145 cells (Fig 4B). Similarly, AZD1480 inhibited (p<0.0001) effectively IL-
6-induced (p=0.002) migration of CWR22Rv1 cells (Suppl. Fig. 3C).  
          To investigate if AZD1480 reduces heterotypic adhesion of PC cells to endothelial cells, DU145 
PC cells were treated with recombinant IL-6 (5 nM) or vehicle with or without AZD1480 (800 nM) for 
72 h and assayed for binding to HUVEC and HBMEC cells (Fig. 4C). Increased heterotypic adhesion of 
DU145 cells to HUVEC (43%) (p<0.0001) and HBMEC cells (63%) (p<0.0001) induced by IL-6 was 
effectively blocked by AZD1480 (HUVEC, p=0.0022); HBMEC, p=0.0011) (Fig. 4C). Similarly, 
increased heterotypic adhesion of CWR22Rv1 cells to HBMEC cells by IL-6 (p=0.04) was inhibited by 
AZD1480 (p<0.0001). 
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Finally, we evaluated if the ability of AZD1480 to block IL-6-driven metastatic behavior of PC 
cells was due to induction of apoptosis in PC cells. Cell viability of DU145 cells cultured with or 
without IL-6 and/or AZD1480 was determined by MTT assay (Fig. 4D). IL-6 showed no effect on 
viability or growth of DU145 cells, indicating that IL-6-driven metastasis formation was not due to IL-6-
stimulated PC cell proliferation. At the same time, AZD1480 failed to decrease the number of viable 
DU145 cells, indicating that suppression of PC cell migration and heterotypic adhesion by AZD1480 
was not caused by AZD1480-induced PC cell death (Fig. 4D). In summary, the data presented here 
demonstrate that AZD1480 specifically blocked the stimulatory effects of IL-6 on PC cell migration and 
heterotypic adhesion, rather than affecting PC cell viability. 
          Stat3 and ERK1/2 mediate IL-6-driven metastases formation in nude mice, which can be 
effectively targeted by pharmacological inhibition of Jak1/2 using AZD1480. Given that IL-6 
promoted metastatic behavior of PC cells in vitro, which was potently inhibited by genetic knockdown 
of both Stat3 and ERK1/2, we investigated if Stat3 and ERK1/2 signaling mediate IL-6-driven 
metastatic colonization in vivo. Most importantly, we wanted to determine if IL-6-induced migratory 
cell phenotype in vitro and metastatic dissemination in vivo can be suppressed pharmacologically using 
the Jak1/2 inhibitor AZD1480.  
          DU145 cells were infected with IL-6 lentivirus (MOI=5) alone or in combination with Stat3-
shRNA lentivirus (MOI=5) and/or ERK1/2-shRNA lentivirus (MOI=5), after which the cells were 
injected into the tail veins of athymic nude mice (Fig. 5). IL-6 induced a 7-fold increase in metastases 
formation (787, S.E.M. = 92) compared to the control group (117, S.E.M = 28) (p<0.0001), which was 
substantially blocked by genetic knockdown of Stat3 alone (146, S.E.M. = 48) (p<0.0001), ERK1/2 
alone (229, S.E.M. = 62) (p<0.0001) or Stat3 and ERK1/2 combined (122, S.E.M. = 44) (p<0.0001) 
(Fig. 5). To evaluate if AZD1480 was able to suppress IL-6-driven metastatic progression of PC, mice 
were treated daily by oral gavage of AZD1480, starting on day 3 until sacrifice. AZD1480 significantly 
 15 
suppressed IL-6-driven metastases formation in these mice (232, S.E.M = 31) (p<0.0001), compared to 
the IL-6 expressing group without AZD1480 treatment (787, S.E.M. = 92) (Fig. 5). Collectively, these 
data demonstrate that pharmacological inhibition of Jak1/2 effectively prevents IL-6-driven metastatic 
colonization of human PC cells in nude mice.  
 
DISCUSSION 
 
          A significant fraction of patients with organ-confined PCs treated by radical prostatectomy 
develop recurrent metastatic disease (41, 42), which suggests that tumor cells with metastatic potential 
may have already disseminated at the time of the primary treatment. Current therapeutic strategies for 
metastatic PC are directed against AR signaling and eventually fail because of progression to the 
castrate-resistant (CR) stage of PC (2-4, 6, 23).  CR PCs are treated with non-targeted cytotoxic 
therapeutic regimens that provide only limited additional survival benefit (2-4, 6, 23). Therefore, 
improved therapeutic strategies are needed both to prevent metastatic dissemination of organ-confined 
PC and to effectively treat existing metastatic disease. In this work, we show for the first time that IL-6-
activated Jak1/2 signaling pathways induce metastatic behavior of AR-positive (CWR22Rv1) and AR-
negative (DU145) PC cells in vitro and excessive metastasis formation in vivo, using experimental 
metastasis assays in mice. These biological pro-metastatic effects were predominantly mediated by Jak-
Stat3 signaling pathway and to a lesser extent by Jak1/2-ERk1/2. Most important from a therapeutic 
perspective, IL-6-driven metastatic progression of PC in vivo was potently suppressed by a small-
molecule pharmacological Jak1/2 inhibitor, AZD1480.  
          To our knowledge, this is the first evidence of IL-6-activated Jak1/2 signaling pathways 
promoting metastatic processes in PC. IL-6 increased PC cell migration, microtubule reorganization and 
heterotypic adhesion of PC cells to vascular endothelial cells, while reducing homotypic PC cell 
adhesion. IL-6 acts to directly upregulate metastatic processes in PC cells, since IL-6 treatment did not 
 16 
increase PC cell viability. Intriguingly, IL-6-activated Jak1/2 signaling resulted in a robust 7-fold 
increase in metastatic colonization of PC cells in the lungs of nude mice. In prior studies, IL-6 has been 
primarily investigated for its growth-promoting ability in PC using various model systems such as 
human PC cell lines, long-term exposure of PC cells to elevated IL-6 concentrations or stable PC cell 
clones overexpressing IL-6 (28-34). Results have been contradictory, with some studies indicating that 
IL-6 stimulation conferred a growth advantage on PC cells, while other studies demonstrated growth-
inhibitory effects of IL-6 on PC cells (28-34). Also, IL-6 has been suggested to induce neuroendocrine 
differentiation of PC cells (51, 52). The current work tested the hypothesis that autocrine IL-6 activation 
of Jak1/2 signaling promotes metastatic progression of PC. The results presented here provide a new 
perspective in understanding the association of autocrine/circulating IL-6 with surrogate markers of 
clinical PC progression in patients, which has been previously demonstrated in numerous studies (10-
16). 
          The biological pro-metastatic effects of IL-6 in DU145 and CWR22Rv1 PC cells were 
predominantly mediated by the Jak1/2-Stat3 pathway in PC cells, while ERK1/2 may also play some 
role in DU145 cells. The findings of the current study are in line with our previous work, which put 
forth a key role for Stat3 in promotion of metastatic dissemination of PC cells in vivo, induction of 
migratory phenotype in vitro and induction of gene expression profiles associated with metastatic 
processes in PC (35, 36). While IL-6 can promote AR signaling in some PC cell models (25-27), a 
recent study demonstrated that IL-6 secreted by endothelial cells promoted metastatic behavior of PC 
cells via downregulation of AR (53). Loss of AR signaling, in turn, resulted in increased TGF-beta 
production, followed by induction of epithelial-to-mesenchymal transition (EMT) and acquisition of an 
invasive PC cell phenotype (53).  Our data presented here, however, show that IL-6 directly promoted 
metastatic processes through Jak1/2 signaling independently of AR, since DU145 cells are negative for 
expression of functional AR. In other words, IL-6 is capable of promoting metastatic behavior of PC 
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cells independently of the AR-TGF-beta-axis. Future work will need to determine if IL-6 is capable of 
promoting metastatic processes simultaneously through multiple signaling pathways, including Jak1/2-
Stat3, Jak1/2-ERK1/2 and AR-TGF-beta in PC cells positive for AR expression. 
          The finding of key clinical importance in the present work is that pharmacological targeting of IL-
6-Jak1/2-Stat3- signaling by the Jak1/2 inhibitor AZD1480 effectively suppressed IL-6-induced 
migratory PC cell phenotype and metastatic dissemination in nude mice. This is critically important 
since numerous Jak1/2 inhibitors are currently in active clinical development for hematopoietic 
proliferative disorders and malignancies (38, 39). Jak1/2 inhibitors could potentially provide an adjuvant 
therapy for organ-confined or locally-advanced PC as a strategy to prevent metastases development after 
primary treatment. In addition, Jak1/2 inhibitors might provide therapeutic benefit for treatment of 
existing metastases in both hormone-responsive and CR PC. In the present work, we also demonstrated 
that IL-6 is expressed in the majority of distant metastases of clinical PCs,  similar to what we have 
previously shown for active Stat3 expression in clinical PC metastases (35). Future work should 
establish if autocrine IL-6 production in PC predicts early development of recurrent metastatic PC. 
Moreover, it will be important to evaluate if IL-6 expression in PC metastases predicts early PC-specific 
death. Finally, IL-6 production/positivity of clinical PCs may serve as a biomarker to identify patients 
who would be most responsive to Jak2-inhibitor-based therapies. Siltuximab (CNTO328), a monoclonal 
antibody against IL-6, has been evaluated in several Phase I and II trials in CRPC in combination with 
chemotherapy or in post-chemotherapy setting (54-56). The efficacy of siltuximab was limited in these 
studies (54-56). However, this may be due to the fact that no patient selection based on Il-6 positivity or 
Stat3 activation of CRPC was conducted. 
          In summary, the findings presented in this work are the first to demonstrate induction of 
metastatic processes in PC by IL-6-Jak1/2-Stat3/ERK1/2 pathways, and the therapeutic potential of 
pharmacological Jak1/2 inhibition as a novel treatment strategy for advanced, metastatic PC.  
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Table 1. IL-6 expression in distant metastases of clinical prostate cancers. 
 
 
 No. of patients %                          
 
 
Prostate cancer metastases  
(lymph node metastases, bone 
metastases and metastases to 
other organs): 
IL-6 expression status; 
Negative 
Positive 
 
Prostate cancer metastases to 
regional lymph nodes: 
IL-6 expression status; 
Negative 
Positive 
 
Prostate cancer metastases to 
bone: 
IL-6 expression status; 
Negative 
Positive 
  
 
 
 
 
 
 
87 
19 
68 
 
 
 
36 
4 
32 
 
 
 
3 
1 
2 
 
 
 
 
 
 
 
100 
22 
78 
 
 
 
100 
11 
89 
 
 
 
100 
33 
67 
Prostate cancer metastases to 
other organs: 
IL-6 expression status; 
Negative 
Positive       
 
 
48 
14 
34 
 
 
100 
29 
71 
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FIGURE LEGENDS 
Figure 1. IL-6 is produced in distant metastases of clinical PCs, and autocrine IL-6 induces 
metastatic colonization of human PC cells in the lungs of nude mice in an experimental metastases 
assay. (A) IL-6 protein is expressed in distant metastases of human PCs. IL-6 in PC metastases was 
analyzed by immunohistochemical staining. Distant PC metastases negative (left) or positive (right) for 
immunostaining of autocrine IL-6 are shown. (B) ELISA demonstrating increased IL-6 protein 
expression in culture media of DU145 cells infected with lentivirus (MOI=5) expressing the IL-6 gene. 
(C) IL-6 increases metastases formation of PC cells to the lungs of athymic nude mice. Athymic nude 
mice were injected with DU145 cells infected with lentivirus expressing IL-6 gene at MOI=5 through 
the tail veins. Increased autocrine IL-6 expression in DU145 cells resulted in a significant increase (71-
fold) (mean 212, S.E.M. 102) compared to control cells (mean 3, S.E.M. 2) (top). Representative 
photographs of India Ink-stained lungs derived from athymic nude mice (bottom).  
 
Figure 2. IL-6 induces a migratory phenotype in PC cells. (A) IL-6 induces migration of PC cells in 
Boyden chamber assays. DU145 cells were cultured in the presence or absence of IL-6 (5 nM) for 72 h, 
counted and equal number of cells in different treatment groups were suspended within the motility 
chamber system using 10% FBS as a chemoattractant. The cells which traversed the membrane pores 
were counted after 16 h. (B) IL-6 induces polarization of the microtubule network in PC cells. DU145 
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cells cultured in the presence or absence of IL-6 (5 nM) for 48 h were fixed and incubated with anti-
tubulin mAb followed by FITC-conjugated secondary antibody. Representative images from one of 
three independent experiments are shown. (C) IL-6 disrupts homotypic adhesion of PC cells. DU145 
cells were seeded on Matrigel, treated with IL-6 (5 nM) for the indicated periods of time and 
morphological alterations were photographed. Note the dispersed and scattered cells in the IL-6 
treatment group. (D) IL-6 induces heterotypic adhesion of PC cells to endothelial cells. DU145 cells 
were cultured in the presence or absence of IL-6 (5 nM) for 72 h, stained with a fluorescent dye and 
allowed to adhere to HUVECs (left) or HBMECs (right) for 60 min, after which the adherent cells were 
quantitated. Averages of three independent experiments are shown. 
 
Figure 3. Stat3 and ERK1/2 signaling mediate the biological effects of IL-6 in induction of 
migratory PC cell phenotype. (A) IL-6 activates phosphorylation of Stat3, ERK1/2 and Jak1/2 but not 
Stat5 or Akt. (i) DU145 cells were serum-starved (0% FBS) overnight followed by stimulation of the 
cells with IL-6 (5 nM) for 20 min and immunoblotted for p(Tyr705)Stat3, Stat3, p(Thr202/Tyr204)ERK, 
ERK1/2 or p(Ser473)Akt or Akt. (ii) Stat5a and Stat5b were immunoprecipitated (IP) and 
immunoblotted for pYStat5a/b and total Stat5a/b. Whole cell lysates of parallel samples were 
immunoblotted for actin. (iii) CWR22Rv1, DU145 and LNCaP cells were serum-starved overnight 
followed by stimulation with IL-6 (5 nM) for 20 min. Jak1 and Jak2 were immunoprecipitated and 
blotted with anti-phosphotyrosine (4G10), anti-Jak1 or anti-Jak2 mAbs. (B) Lentivirus expressing 
shRNAs targeting Stat3, ERK1 and ERK2 expression in DU145 cells. DU145 cells infected with each 
lentiviral construct were immunoblotted with anti-Stat3, anti-actin, anti-ERK1 or anti-ERK2 antibodies. 
(C) Inhibition of Stat3 and/or ERK1/2 by RNA interference blocks IL-6-induced PC cell migration. 
DU145 cells were cultured in the presence of 1% CS-FBS and infected with lentiviruses expressing 
control-shRNA, Stat3-shRNA and/or ERK1/2-shRNA (MOI=5) and treated with or without IL-6 (5 nM) 
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for 72 h. Cells were counted and equal numbers of cells in each treatment group were assayed for 
migration in Boyden chambers for 16 h. (D) Inhibition of Stat3 and/or ERK1/2 signaling blocks IL-6-
induced increase in adhesion of PC cells to endothelial cells. DU145 cells were cultured in the presence 
of 1% CS-FBS and infected with lentiviruses expressing control-shRNA, Stat3-shRNA and/or ERK1/2-
shRNA (MOI=5) and treated with or without IL-6 (5 nM) for 72 h. Cells were stained with a fluorescent 
dye and allowed to adhere to HBMEC cells for 60 min followed by quantitation of adhered cells by 
fluorescent reader. Averages of three independent experiments are shown. 
 
Figure 4. Pharmacological Jak1/2 inhibitor AZD1480 suppresses IL-6-activated Stat3 and ERK1/2 
signaling in PC cells and IL-6-induced migratory PC cell phenotype. (A) AZD1480 disrupts IL-6-
induced phosphorylation of Stat3 and ERK1/2 in PC cells. DU145 cells were serum-starved (0% FBS) 
overnight, pre-treated with AZD1480 at indicated concentrations for 1 h followed by stimulation of the 
cells with IL-6 (50 nM) for 20 min and immunoblotted for anti-p(Tyr705)Stat3, anti-
p(Thr202/Tyr204)ERK, anti-Stat3, anti-ERK1/2 or anti-Actin, as indicated. (B) AZD1480 inhibits IL-6-
induced migration of DU145 cells. DU145 cells were cultured in 1% CS-FBS in the presence or absence 
of IL-6 (5 nM) with or without pre-treatment of the cells with AZD1480 (800 nM). Equal numbers of 
cells in each treatment group were analyzed for migration in Boyden chambers for 16 h (upper panel). 
Cell lysates from parallel wells were immunoblotted for anti-p(Tyr705)Stat3, anti-
p(Thr202/Tyr204)ERK, Stat3, or anti-actin (lower panel). (C) AZD1480 inhibits IL-6-induced 
heterotypic adhesion of PC cells to endothelial cells. DU145 cells were cultured in 1% CS-FBS in the 
presence or absence of IL-6 (5 nM) with or without pre-treatment of the cells with AZD1480 (800 nM). 
Averages of three independent experiments are shown. (D) IL-6 or AZD1480 did not affect the viability 
of DU145 cells. (i) DU145 cells were cultured in 1% CS-FBS for 7 days in the presence or absence of 
IL-6 (5 nM). The bars represent the numbers of viable DU145 cells in both treatment groups at indicated 
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times. (ii) The number of DU145 cells cultured in 1% CS-FBS for 7 days in the presence or absence of 
AZD1480 at indicated concentration. 
 
Figure 5. Pharmacological Jak1/2 inhibitor AZD1480 blocks IL-6-Jak-Stat3/ERK1/2-driven 
metastases formation in nude mice. Genetic knockdown of Stat3 and/or ERK1/2, as well as 
pharmacological inhibition of Jak1/2 by AZD1480, suppresses PC metastases formation in nude mice. 
DU145 cells infected with lentivirus expressing IL-6 (MOI=5) with or without simultaneous infection of 
lentiviruses expressing shRNA-Stat3 (MOI=5) and/or shRNA-ERK1/2 (MOI=5) were injected in 
athymic nude mice through tail veins. AZD1480 was administered to indicated groups of mice daily by 
oral gavage (50 mg/kg). The lungs were stained with India Ink and scored for surface metastases. 
Representative photographs of India Ink-stained lungs (lower panel). 
 
 
 
 
 
 
 
 
 
 
 
 
 
